Stryker Corporation (NYSE:SYK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Stryker Corporation (NYSE:SYK) have been given an average rating of “Moderate Buy” by the twenty-four brokerages that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $386.28.

SYK has been the subject of several recent analyst reports. Royal Bank Of Canada lowered their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Argus set a $370.00 price objective on Stryker in a report on Thursday, July 9th. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Needham & Company LLC dropped their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Finally, Citigroup reaffirmed a “buy” rating on shares of Stryker in a research report on Thursday, August 13th.

Stryker Trading Down 2.3%

Shares of NYSE SYK opened at $322.20 on Friday. Stryker has a 1-year low of $281.00 and a 1-year high of $396.86. The stock has a market capitalization of $123.58 billion, a P/E ratio of 33.39, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The business has a fifty day moving average price of $328.64 and a 200 day moving average price of $331.47.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

Insider Activity

In related news, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This trade represents a 11.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 over the last 90 days. 4.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Stryker

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Varma Mutual Pension Insurance Co raised its holdings in shares of Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after purchasing an additional 5,100 shares during the last quarter. QRG Capital Management Inc. lifted its position in Stryker by 7.4% during the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after purchasing an additional 4,186 shares during the period. Swedbank AB boosted its holdings in Stryker by 6.6% in the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after purchasing an additional 7,934 shares during the last quarter. Crossmark Global Holdings Inc. grew its position in Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after purchasing an additional 6,367 shares during the period. Finally, Royal Bank of Canada grew its position in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after purchasing an additional 199,863 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.